University of Freiburg

Job Research Foundation Announces 2024 Grant Recipient

Retrieved on: 
Tuesday, March 12, 2024
Boston Children's Hospital, University of Pennsylvania, Disease, University of Freiburg, Associate, Patient, Hyperimmunoglobulin E syndrome, Research, Gene editing, Rockefeller University, Columbia University, University, Hospital, Aarhus University, Multimedia, University of Newcastle, Barber–Say syndrome, Pharmaceutical industry

NEW YORK, March 12, 2024 /PRNewswire/ -- The Job Research Foundation was established to underwrite research into Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), a rare multisystem immunodeficiency disorder.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- The Job Research Foundation was established to underwrite research into Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), a rare multisystem immunodeficiency disorder.
  • This year's recipient, Dr. Rasmus O. Bak, Associate Professor at Aarhus University in Denmark, will receive a grant totaling $200,000.
  • Since 2019 the Job Research Foundation has funded a total of 15 scientific research projects.
  • The Job Research Foundation will start accepting the next round of grant applications in July 2024.

EH Group Joins H2MARINE Project to Develop Next Generation Maritime Fuel Cells

Retrieved on: 
Thursday, February 29, 2024
Environmental Issues, Alternative Energy, Energy, Technology, Environment, Green Technology, Engineering, Maritime, Transport, Other Technology, Climate Change, Manufacturing, Hydrogen, EH, ZSW, Multimedia, DANA, FC, FCS, Entrepreneurship, Beyond Gravity, University, EPFL, VTT, University of Freiburg, ThyssenKrupp Marine Systems, PEM, Pressure, Renewable energy

EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).

Key Points: 
  • EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).
  • The project is committed to innovation in hydrogen technologies, focused on the development of next generation PEM fuel cell stacks for marine applications.
  • Based on its unique FC technology, EH Group will contribute its high power density stacks, further developed and optimised for marine use.
  • “Our high power density fuel cell technology has been recognised in its use for maritime applications, and we are delighted to contribute to its further development in this project.

IEEE EMBS Executive Committee Appoints Dr. Erika Ross Ellison as President-Elect, Along With Two New Vice Presidents

Retrieved on: 
Tuesday, December 19, 2023
Technology, Medical Devices, Science, Genetics, Biotechnology, Other Manufacturing, Health, Health Technology, Engineering, Other Science, Research, Nanotechnology, Manufacturing, Software, Hardware, Data Management, Artificial Intelligence, FH, Student, Biomedical sciences, Tetraplegia, Mayo Clinic, Electrical engineering, University, Machine learning, Bachelor of Science, Signal processing, UNSW, EMBC, Speech, Doctor of Philosophy, Conference, Texas A&M University, Telstra, Clinical, Telecommunications, Biology, School, Student activities, Woman, DRS, Applied science, University of Freiburg, Molecular biology, Quality, American Speech, Neurosurgery, Growth, Aalborg University, Medical device

Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.

Key Points: 
  • Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.
  • “My top objective will be to establish IEEE EMBS as the largest global forum for biomedical engineers, clinicians and scientists,” said Dr. Ross Ellison.
  • She is the technical representative on the IEEE EMBS administrative committee, and served as program co-chair of EMBC 2023.
  • She is an IEEE EMBS practitioner representative, and is active on the IEEE Brain steering committee.

IEEE EMBS Hosts Data Science and Engineering Conference in Malta to Promote Data Revolution in Healthcare, Medicine and Biology

Retrieved on: 
Monday, November 20, 2023
Manufacturing, Nanotechnology, Other Science, Research, Oncology, Software, Artificial Intelligence, Medical Devices, Internet, Hardware, Genetics, Data Management, Science, Technology, Biotechnology, Health, Engineering, Health Technology, University of Freiburg, Wang, European Institute, Data science, Executive Committee, Georgia Tech, National University of Singapore, Data engineering, University of Ioannina, University of Malta, MD Anderson Cancer Center, Gesellschaft mit beschränkter Haftung, Biomedicine, Machine learning, University of Houston, Conference, University, Columbia University, AI, Innovation, Biomedical engineering, National university, Pharmaceutical industry, IEEE, Medicine, Surgical oncology, Cancer, Health care

IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), today announced the inaugural International Conference on Data Science and Engineering in Healthcare, Medicine & Biology taking place from December 7-9, 2023 in St. Julians, Malta.

Key Points: 
  • IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), today announced the inaugural International Conference on Data Science and Engineering in Healthcare, Medicine & Biology taking place from December 7-9, 2023 in St. Julians, Malta.
  • The conference is structured as a three-day program including three mini-symposiums on (1) Data Science in Healthcare; (2) Data Engineering in Cancer and (3) Data Science in Surgical Oncology.
  • Additionally, the posters presented at the conference cover topics regarding data science as it applies to healthcare, medical imaging, personalized medicine, mind and body, women’s health, heterogeneous data harmonization, and others.
  • “EMBS recognizes the current renaissance of data science as AI and machine learning continue to evolve and open new doors in the field.

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

Retrieved on: 
Monday, June 26, 2023
Biotechnology, Pharmaceutical, Health, Veterinary, Boehringer Ingelheim Animal Health, Leibniz Institute for Polymer Research, Merck & Co., DSM, University, Therapy, Veterinary medicine, Global health, Multimedia, Animal Health, Doctor of Philosophy, Max Planck Institute for Polymer Research, Chemistry, Novo Holdings A/S, Dog, Max Planck Society, University of Freiburg

Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.

Key Points: 
  • Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20230626564216/en/
    Dr. Marcus Remmers joins the board of directors at Invetx.
  • (Photo: Business Wire)
    “We are pleased to welcome Dr. Remmers, an accomplished life sciences executive with significant veterinary biologics and animal health expertise, to our board of directors,” said Juergen Horn, PhD, chief executive officer, Invetx.
  • “I am excited to join the board of directors of Invetx and be part of the company’s remarkable journey,” said Dr. Remmers.

Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer

Retrieved on: 
Tuesday, May 30, 2023
Buckland Hospital, Carcinoma, Bevacizumab, Drug development, Oncolytics Biotech, Pharmacovigilance, Roche, Infection, Cancer, Breast, University Hospital of Basel, Genentech, Doctor of Philosophy, Teaching hospital, Surgical oncology, Novartis, MD, Patient, Gastrointestinal disease, SAN, Paclitaxel, University of Freiburg, Therapy, Breast cancer, Pharmaceutical industry, Medical device

"We are excited to announce the appointment of Dr. Laeufle as Chief Medical Officer of Phanes.

Key Points: 
  • "We are excited to announce the appointment of Dr. Laeufle as Chief Medical Officer of Phanes.
  • Dr. Laeufle has played a key role in supporting our clinical programs during the past seven months as our Chief Medical Adviser," said Dr. Ming Wang, Founder and CEO.
  • With Dr. Laeufle's appointment, Phanes is well positioned to make important impacts in delivering innovative therapies for cancer patients."
  • Prior to joining Phanes, Dr. Laeufle served as Chief Medical Officer at Imugene Biotech, responsible for developing B-cell activating immunotherapies (neoHERIZON study).

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology

Retrieved on: 
Thursday, January 12, 2023
National Health Council, Electricity, Institute of Electrical and Electronics Engineers, Computational Biology Department, Algorithm, American Institute, Doctor of Philosophy, Medicine, Biological engineering, Biomedical engineering, Machine learning, Biomarker, California Institute of Technology, Knowledge, Carnegie Mellon University, Professor, Electronics, Columbia University, Artificial intelligence, CORE, Patent, Research, Cancer, CMU, Columbia, American Institute for Medical and Biological Engineering, University of Freiburg, Probability, Medical imaging, Pharmaceutical industry, Biology, Biochemistry

He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.

Key Points: 
  • He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.
  • His experience with ground-breaking research is vital to the evolution of our predictive models and goal to discover more effective cancer therapies,” said Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board.
  • Predictive Oncology is changing the landscape of oncology drug discovery with a new category that goes beyond artificial intelligence.
  • In addition to his role as head of Computational Biology Department at CMU, Dr. Murphy has also served as Professor of Biological Sciences, Biomedical Engineering, and Machine Learning there.

Mathias Romacker Selected as the Newest Member of the Kymanox Executive Advisor Team

Retrieved on: 
Tuesday, December 20, 2022
Universe, Biotechnology, Barbara Romack, Pfizer, PDA, Parenteral Drug Association, University of Freiburg, Conference, Ministry of Education (Malaysia), KEA, Triangle Park (Quezon City), Pharmaceutical industry, Management, Economics

Los Angeles, California, USA and Research Triangle Park, North Carolina, USA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services organization supporting biotechnology, pharmaceutical, medical device, and combination product industries, announced the addition of well-known and experienced professional, Mathias Romacker, to the Kymanox Executive Advisor (KEA) team.

Key Points: 
  • Los Angeles, California, USA and Research Triangle Park, North Carolina, USA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services organization supporting biotechnology, pharmaceutical, medical device, and combination product industries, announced the addition of well-known and experienced professional, Mathias Romacker, to the Kymanox Executive Advisor (KEA) team.
  • With its diverse team of industry experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market.
  • Kymanox Executive Advisors provide strategic guidance to the company and leverage deep relationships in the global life science community to help the company’s clients and their programs achieve success.
  • To learn more about how Kymanox can help you with your life science engineering challenges, contact us at [email protected] or visit www.kymanox.com today.

Labroots Hosts 5th CRISPR Virtual Event on November 2nd, 2022

Retrieved on: 
Thursday, October 27, 2022
Therapy, Genetic engineering, Genomics, Science, Assistant, Melissa Chaty, Infection, Organic acid, Virus, Rice University, Synthetic biology, Medicine, Learning, PCR, COVID-19, Gene editing, LinkedIn, Planning committee, MIT, Biology, FIT, IMTEK, Research, Biological engineering, RNA, Biosensor, University of Freiburg, Social, Severe acute respiratory syndrome coronavirus 2, Department, University, Environment, Twitter, Rice, Antibiotics, Medical device, Vaccine, Online shopping, Diagnosis, CRISPR, News, Labroots, Facebook, Genetics

YORBA LINDA, Calif., Oct. 27, 2022 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is delighted to announce its 5th annual CRISPR virtual event. The free, online event builds on previous years events and advances the conversations happening around sessions such as CRISPR Biology, CRISPR in Diagnostics, and CRISPR in Disease Therapy. This event will take place on November 2, 2022.

Key Points: 
  • The global meeting will focus on CRISPR-Cas systems, genetic engineering technologies, novel approaches to cell and gene therapy, and emerging discoveries pushing the boundaries of CRISPR research
    YORBA LINDA, Calif., Oct. 27, 2022 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, is delighted to announce its 5th annual CRISPR virtual event.
  • The free, online event builds on previous years events and advances the conversations happening around sessions such as CRISPR Biology, CRISPR in Diagnostics, and CRISPR in Disease Therapy.
  • "Our annual CRISPR virtual event has been a benchmark in the field and continues to highlight creative new CRISPR technologies and further progress genome engineering revolutionizing biological research while making groundbreaking inroads to therapies," said Greg Cruikshank, Chief Executive Officer of Labroots.
  • Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

Retrieved on: 
Thursday, October 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Constellation, Philippe Ciais, Gemstone, Doctor of Philosophy, Therapy, Computer, Head, Cambridge Crystallographic Data Centre, ChemMedChem, Cell engineering, Multiple myeloma, Bortezomib, Patient, Pharmacy, CMC, Computational chemistry, Drug discovery, Multiplicity of infection, Negotiation, Harvard University, Journal, University of Freiburg, Medicinal chemistry, University, Biophysics, Journal of Medicinal Chemistry, Data science, Biochemistry, Fine chemical, Pharmaceutical industry, MorphoSys, Chemistry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.
  • Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMines operations at its European offices in Basel, Switzerland.
  • Martin and Louis are stellar additions to the LifeMine executive team and share in our vision to reinvent small molecule drug discovery through genomic search and retrieval from the biosphere, said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine.
  • Martin and Louis experience and expertise will only help further accelerate our efforts.